Clinical trial
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian…
NCT00418093 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00418093 |
|---|---|
| Title | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
| Official title | A Phase II Evaluation of Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Brigham and Women's Hospital Eli Lilly and Company Industry Sanofi-Synthelabo Genentech, Inc. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Oxaliplatin, Bevacizumab |
| Enrollment | 19 |
| Start date | Sep 1, 2006 |
| Primary completion | Jan 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Jan 4, 2007 |
| Last update posted | Jun 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: